Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln
13/05/2026 06:37
May 13 (Reuters) - Sprint Bioscience AB SPRINT.ST: Q1 NET SALES AMOUNT TO 0 MSEK Q1 OPERATING RESULT AT -14.3 MSEK Source text: ID:nMFN8QjjXm Further company coverage: SPRINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln